GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (STU:SP4P) » Definitions » Cash Ratio

Achieve Life Sciences (STU:SP4P) Cash Ratio : 3.23 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Achieve Life Sciences Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Achieve Life Sciences's Cash Ratio for the quarter that ended in Mar. 2024 was 3.23.

Achieve Life Sciences has a Cash Ratio of 3.23. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Achieve Life Sciences's Cash Ratio or its related term are showing as below:

STU:SP4P' s Cash Ratio Range Over the Past 10 Years
Min: 0.74   Med: 3.44   Max: 12.22
Current: 3.23

During the past 13 years, Achieve Life Sciences's highest Cash Ratio was 12.22. The lowest was 0.74. And the median was 3.44.

STU:SP4P's Cash Ratio is ranked better than
51.15% of 1476 companies
in the Biotechnology industry
Industry Median: 3.025 vs STU:SP4P: 3.23

Achieve Life Sciences Cash Ratio Historical Data

The historical data trend for Achieve Life Sciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Cash Ratio Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.81 12.21 9.45 1.14 0.74

Achieve Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 7.26 4.87 0.74 3.23

Competitive Comparison of Achieve Life Sciences's Cash Ratio

For the Biotechnology subindustry, Achieve Life Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Cash Ratio falls into.



Achieve Life Sciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Achieve Life Sciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=14.21/19.086
=0.74

Achieve Life Sciences's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=61.086/18.927
=3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achieve Life Sciences  (STU:SP4P) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Achieve Life Sciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences (STU:SP4P) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences (STU:SP4P) Headlines

No Headlines